Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.1B
30M shares
52-week range
$31.44 – $56.64
12% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $859.6M | $955.1M | $862.5M | $1.01B | $1.05B | $1.24B | $1.31B | $1.37B |
| Cost of revenue | $390.5M | $430.4M | $402.2M | $442.6M | $474.2M | $568.5M | $574.0M | $649.1M |
| Gross profit | $469.1M | $524.7M | $460.3M | $568.0M | $571.2M | $676.2M | $733.0M | $725.4M |
| Gross margin | 54.6% | 54.9% | 53.4% | 56.2% | 54.6% | 54.3% | 56.1% | 52.8% |
| R&D | $42.2M | $45.5M | $40.5M | $43.6M | $47.2M | $52.6M | $54.4M | $55.9M |
| Operating income | $71.3M | $79.1M | $46.0M | $109.7M | $70.1M | $120.6M | $200.3M | $141.1M |
| EBITDA | $133.1M | $146.2M | $118.3M | $179.3M | $7.8M | $192.5M | $272.2M | $154.5M |
| Net income | $40.9M | $28.6M | $9.5M | $62.5M | −$80.6M | $64.5M | $132.4M | $47.1M |
| Net margin | 4.8% | 3.0% | 1.1% | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
| EPS (diluted) | 1.41 | 0.97 | 0.32 | 1.94 | -2.68 | 2.04 | 4.26 | 1.51 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.4B | $4.37 | $4.34–$4.38 | 3 |
| 2027 | $1.4B | $4.79 | $4.63–$4.94 | 3 |
| 2028 | $1.5B | $5.43 | $5.40–$5.47 | 1 |
Forward consensus · source: Financial Modeling Prep
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
www.conmed.comNo one on the platform currently holds CNMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 76,581 | $5.5M |
| Bridgewater Associatesas of 2025-09-30 | 5,933 | $279.0K |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-09-15 | $0.2000 | 2025-10-03 |
| 2025-06-13 | $0.2000 | 2025-07-03 |
| 2025-03-14 | $0.2000 | 2025-04-04 |
| 2024-12-20 | $0.2000 | 2025-01-03 |
| 2024-09-16 | $0.2000 | 2024-10-04 |
| 2024-06-14 | $0.2000 | 2024-07-05 |
| 2024-03-14 | $0.2000 | 2024-04-05 |
| 2023-12-15 | $0.2000 | 2024-01-05 |
| 2023-09-14 | $0.2000 | 2023-10-05 |
No one on the platform has traded CNMD yet.
| $847M |
| — |
| KMTSKestra Medical Technologies, Ltd. | $25.35 | -4.09% | $1.5B | — |
| NEOGNeogen Corporation | $9.10 | -5.01% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 9.1× earnings vs its 44.5× historical median P/E.
Fair value ≈ $169.08 · price $34.41 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CNMD Really good write-up that perfectly summarizes CNMD's present situation. So if you want to bring your CNMD knowledge up to date or just discover CNMD, this is required reading. https://everyticker.com/quote/CNMD/analysis/conmed-s-surgical-transformation-three-platforms-one-focus-and-the-path-to-medtech-premium-valuation-nasdaq-cnmd
View on StockTwits ↗$CNMD Current Stock Price: $35.07 Contracts to trade: $35.0 CNMD May 15 2026 Call Entry: $0.70 Exit: $1.20 ROI: 71% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$CNMD Share Price: $36.71 Contract Selected: Nov 20, 2026 $35 Calls Buy Zone: $4.45 – $5.50 Target Zone: $7.79 – $9.52 Potential Upside: 65% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$CNMD Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.45 up 136.84% YoY • Reported revenue of $317.05M down -1.31% YoY • Conmed is raising its full-year 2026 organic constant currency revenue growth outlook to 5.0% to 6.5% and expects reported revenue of $1.350 billion to $1.375 billion. Conmed reaffirms full-year adjusted diluted net earnings per share in the range of $4.30 to $4.45.
View on StockTwits ↗$CMPX $CNMD $AGAE @judgeyoung2 cubie teaches thats why u read a person's post history to see how often they are Right Vs Wrong, when these tards are wrong almost 90-100% time. u do the opposite judge, cubie's teaches 🤭🫡
View on StockTwits ↗@judgeyoung2 yea coin flip, but this noob is contrarian so be careful , hes pumping $CMPX now after $CNMD $AGAE no bueno😅🙄
View on StockTwits ↗$CNMD https://anachart.com/wp-content/uploads/ana_temp/1773745269_soc-img.jpg
View on StockTwits ↗$CNMD has headwinds — but the growth drivers are still in play ⚖️ AirSeal, Buffalo Filter, and BioBrace remain key growth engines as supply chains normalize, though tariffs and a GI exit are putting pressure on EPS. See why the stock may still deserve a spot in your portfolio 👉 https://www.zacks.com/stock/news/2881663/heres-why-you-should-retain-conmed-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2881663-teaser-36727&ADID=SYND_STOCKTWITS_TWEET_2_2881663_TEASER_36727
View on StockTwits ↗$CNMD down 27.1% in six months — what's dragging it down? 📉 ⚠️ Tariff headwinds and higher operating expenses are impacting EPS. 🔄 Strategic exit from gastroenterology aims to boost margins long-term. 📊 Q1 2026 revenue and EPS estimates suggest declines from the year-ago period. Full analysis here 👉 https://www.zacks.com/stock/news/2881663/heres-why-you-should-retain-conmed-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2881663-body-36725&ADID=SYND_STOCKTWITS_TWEET_2_2881663_BODY_36725
View on StockTwits ↗$CNMD Share Price: $45.15 Contract Selected: Aug 21, 2026 $45 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.55 – $5.56 Potential Upside: 69% ROI Time to Expiration: 180 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$CNMD - CONMED Corporation - 10K - Updated Risk Factors CNMD’s 2026 10-K sharpens legal and regulatory landmines (global anti-bribery, healthcare, FDA and privacy regimes), adds detailed capital-structure and interest-rate risks (new secured debt, convertibles, leverage, preferreds, dividends halted), flags heavier geopolitical, reimbursement, cyber/AI, distribution, divestiture and international exposure, and underscores dependence on key partners and talent. #HealthcareIndustry #RegulatoryCompliance #FinancialRisk #GeopoliticalRisk #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/CNMD/10-K/2026-02-17
View on StockTwits ↗Why I’m holding $CNMD — patience could pay here 👀 CONMED’s growth story is anchored in AirSeal, Buffalo Filter, and BioBrace as supply chains normalize, even though tariffs and a GI exit are pressuring EPS in the near term. Is this a steady hold while the setup improves? Full view here 👉 https://www.zacks.com/stock/news/2848399/heres-why-you-should-retain-conmed-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2848399-teaser-32944&ADID=SYND_STOCKTWITS_TWEET_2_2848399_TEASER_32944
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.